Morphic Holding, Inc. (MORF) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Waltham, MA, アメリカ. 現CEOは Praveen P. Tipirneni.
MORF を有する IPO日 2019-06-27, 128 名の正社員, に上場 NASDAQ Global Market, 時価総額 $2.86B.
Morphic Holding, Inc. is a biopharmaceutical company focused on discovering and developing oral small-molecule integrin therapeutics to treat autoimmune, cardiovascular, metabolic, fibrotic, and oncologic diseases. The company's lead candidate, MORF-057, is an α4β7-specific integrin inhibitor currently in Phase 1 clinical trials for inflammatory bowel disease, with preclinical programs targeting idiopathic pulmonary fibrosis and other fibrotic conditions. Morphic is also advancing programs in αvβ6 for fibrotic diseases and αvβ8 for solid tumors through its proprietary integrin technology platform. The company has established research collaborations and licensing agreements with major partners including AbbVie, Janssen Pharmaceuticals, and Children's Medical Center Corporation to accelerate integrin-based drug development. Founded in 2014 and headquartered in Waltham, Massachusetts, Morphic leverages its integrin technology expertise to address significant unmet medical needs across multiple therapeutic areas.
